172 related articles for article (PubMed ID: 32679272)
1. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.
O'Connor LP; Wang AZ; Yerram NK; Lebastchi AH; Ahdoot M; Gurram S; Zeng J; Mehralivand S; Harmon S; Merino MJ; Parnes HL; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Urology; 2020 Oct; 144():164-170. PubMed ID: 32679272
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy.
Williams C; Khondakar NR; Daneshvar MA; O'Connor LP; Gomella PT; Mehralivand S; Yerram NK; Egan J; Gurram S; Rompré-Brodeur A; Webster BR; Owens-Walton J; Parnes H; Merino MJ; Wood BJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2021 Nov; 206(5):1157-1165. PubMed ID: 34181465
[TBL] [Abstract][Full Text] [Related]
3. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
5. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
Klotz L; Pond G; Loblaw A; Sugar L; Moussa M; Berman D; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Haider M
Eur Urol; 2020 Mar; 77(3):311-317. PubMed ID: 31708295
[TBL] [Abstract][Full Text] [Related]
6. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
7. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
Shapiro DD; Gregg JR; Lim AH; Nogueras-González GM; Choi H; Kang HC; Inguillo IA; Chapin BF; Davis JW; Ward JF
BJU Int; 2021 Mar; 127(3):340-348. PubMed ID: 32357283
[TBL] [Abstract][Full Text] [Related]
8. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
9. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
10. Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
Bloom JB; Hale GR; Gold SA; Rayn KN; Smith C; Mehralivand S; Czarniecki M; Valera V; Wood BJ; Merino MJ; Choyke PL; Parnes HL; Turkbey B; Pinto PA
J Urol; 2019 Jan; 201(1):84-90. PubMed ID: 30577395
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.
Kinnaird A; Yerram NK; O'Connor L; Brisbane W; Sharma V; Chuang R; Jayadevan R; Ahdoot M; Daneshvar M; Priester A; Delfin M; Tran E; Barsa DE; Sisk A; Reiter RE; Felker E; Raman S; Kwan L; Choyke PL; Merino MJ; Wood BJ; Turkbey B; Pinto PA; Marks LS
J Urol; 2022 Apr; 207(4):823-831. PubMed ID: 34854746
[TBL] [Abstract][Full Text] [Related]
13. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer.
Kesch C; Schütz V; Dieffenbacher S; Bonekamp D; Hadaschik BA; Hohenfellner M; Radtke JP
Curr Opin Urol; 2018 Mar; 28(2):172-177. PubMed ID: 29083999
[TBL] [Abstract][Full Text] [Related]
15. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
[TBL] [Abstract][Full Text] [Related]
16. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
17. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies.
Gallagher KM; Christopher E; Cameron AJ; Little S; Innes A; Davis G; Keanie J; Bollina P; McNeill A
BJU Int; 2019 Mar; 123(3):429-438. PubMed ID: 30113755
[TBL] [Abstract][Full Text] [Related]
18. Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance.
Wang M; Lange A; Perlman D; Qi J; George AK; Ferrante S; Semerjian A; Sarle R; Cher ML; Ginsburg KB;
Prostate; 2023 Sep; 83(12):1141-1149. PubMed ID: 37173808
[TBL] [Abstract][Full Text] [Related]
19. Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance.
O'Connor LP; Wang AZ; Yerram NK; Long L; Ahdoot M; Lebastchi AH; Gurram S; Zeng J; Harmon SA; Mehralivand S; Merino MJ; Parnes HL; Choyke PL; Shih JH; Wood BJ; Turkbey B; Pinto PA
Eur Urol Oncol; 2021 Apr; 4(2):227-234. PubMed ID: 33867045
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]